Cell-free ligand binding assays for nuclear receptors.
There has been tremendous progress in the development of ligand binding assays for NRs during the past several years. A major development has been the advent of homogeneous assay formats, including those that do not require a radioligand. These high throughput, low volume assay formats will be powerful tools for the identification and characterization of novel NR ligands, including both natural ligands for orphan NRs and new drugs that mediate their therapeutic effects through this class of receptors.
Jones
Stacey A
SA
GlaxoSmithKline, Research Triangle Park, North Carolina 27709-3398, USA.
Parks
Derek J
DJ
Kliewer
Steven A
SA
D000818:Animals; D001671:Biochemistry / Q000379:methods*; D002474:Cell-Free System; D002850:Chromatography, Gel; D004268:DNA-Binding Proteins / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000737:chemistry; D047629:Estrogen Receptor beta; D031541:Fluorescence Resonance Energy Transfer / Q000379:methods; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear / Q000737:chemistry*; D011960:Receptors, Estrogen / Q000378:metabolism; D014157:Transcription Factors / Q000737:chemistry; D000099150:Receptor, Farnesoid X-Activated
D004268:DNA-Binding Proteins; D004958:Estradiol; D047629:Estrogen Receptor beta; D008024:Ligands; D018160:Receptors, Cytoplasmic and Nuclear; D011960:Receptors, Estrogen; D014157:Transcription Factors; D000099150:Receptor, Farnesoid X-Activated